基因编辑工具的分子作用机制及其应用、药物靶标发现与确证、以及药物/靶点互作的构效关系

以第一或通讯作者在Science、Nature、Cell、Nature Communications、NAR和JMC等杂志发表论文多篇。
近两年作为项目主要负责人参与新药转化项目多项，合同金额超过1.4亿元。
现承担国家自然科学基金面上项目（主持）、国家重点研发计划（课题负责人）等课题。

1. Yuan K, Li Z, Kuang W, Wang X, Ji M, Chen W, Ding J, Li J, Min W, Sun C, Ye X, Lu M, Wang L, Ge H, Jiang Y, Hao H, Xiao Y, Yang P. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nat Commun. 2022 May 25;13(1):2903. doi: 10.1038/s41467-022-30581-4. PMID: 35614066; PMCID:PMC9133015.
2. Wang T, Cai S, Cheng Y, Zhang W, Wang M, Sun H, Guo B, Li Z, Xiao Y, Jiang S. Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation. J Med Chem. 2022 Mar 10;65(5):3879-3893. doi:10.1021/acs.jmedchem.1c01682. Epub 2022 Feb 21. PMID: 35188766.
3. Wang X, Yuan Q, Zhang W, Ji S, Lv Y, Ren K, Lu M, Xiao Y. Sequence specific integration by the family 1 casposase from Candidatus Nitrosopumilus koreensis AR1. Nucleic Acids Res. 2021 Sep 27;49(17):9938-9952. doi:10.1093/nar/gkab725. PMID: 34428286; PMCID: PMC8464041.
4. Xiao Y, Luo M, Dolan AE, Liao M, Ke A. Structure basis for RNA-guided DNA degradation by Cascade and Cas3. Science. 2018 Jul 6;361(6397):eaat0839. doi:10.1126/science.aat0839. Epub 2018 Jun 7. PMID: 29880725; PMCID: PMC6537108.
5. Xiao Y, Ng S, Nam KH, Ke A. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration. Nature. 2017 Oct 5;550(7674):137-141.doi: 10.1038/nature24020. Epub 2017 Sep 4. PMID: 28869593; PMCID: PMC5832332.
6. Xiao Y, Luo M, Hayes RP, Kim J, Ng S, Ding F, Liao M, Ke A. Structure Basis for Directional R-loop Formation and Substrate Handover Mechanisms in Type I CRISPR-Cas System. Cell. 2017 Jun 29;170(1):48-60.e11. doi:10.1016/j.cell.2017.06.012. PMID: 28666122; PMCID: PMC5841471.